To observe the therapeutic effect of Longqing tablets in treating chronic prostatitis (damp-heat stasis obstruction pattern) accompanying erectile dysfunction. Methods： One hundred and eight patients with chronic prostatitis accompanying ED were given the U.S. National Institutes of Health chronic prostatitis symptom score (NIH-CPSI) and the International Index of Erectile Function questionnaire 5 (IIEF-5) score before treatment. All the patients were randomly divided into control group (n=54), the treatment group (n=54). Control group applied oral administration of terazosin hydrochloride tablets (semaxanib), 2 mg per time before bedtime consecutively for 8 weeks. Treatment group applied oral administration of Longqing tablets, 6 pills per time, 2 times a day for 8 weeks. Results： After 8 weeks of treatment, NIH-CPSI score of patients in the control group was 13.0 ± 5.5 points, which was significantly improved compared with that before treatment (21.3 ± 2.2 points) (P<0.05); IIEF-5 score was 12.4 ± 3.4 points which showed no significant improvement compared with that before treatment (13.5 ± 3.4 points), (P>0.05); NIH-CPSI score of patients in the treatment group was 12.4 ± 5.4 points, and IIEF-5 score was 16.2 ± 4.3points, both of which showed significant improvement compared with what it was before the treatment (P<0.05). The total effective rate for ED of the control group was 32.65%, and that of the treatment group was 68.63%, and the difference between the two groups was significant (P<0.01). Conclusion： Application of Longqing tablets in treating chronic prostatitis (heat stasis) associated with ED can significantly improve symptoms of chronic prostatitis, and meanwhile shows good effect ED, hence it is worth being generalized in clinical practice.